Although fascaplysin is a toxic compound whose cytotoxic effect is not specific to RMS [23], our observation suggests that it is feasible to develop pharmacologic inhibitors of Cdk4 as therapeutics for ARMS. This evidence concerns the gene CDK4 and alveolar rhabdomyosarcoma.